Pipeline
| Program | Indication |
Discovery |
Preclinical |
IND |
Ph l |
|
|---|---|---|---|---|---|---|
|
ADC |
PLB-001 |
Lung Cancer |
|
2026 Q1 |
2026 Q2 (China) 2026 Q3(outside of China) |
|
|
PLB-002 |
Ovarian Cancer |
|
2025 Q3 |
2025 Q4 (China) 2026 Q1(outside of China) |
||
|
PLB-003 |
Solid tumors |
|
|
|
||
|
PLB-004 |
Solid tumors |
|
|
|
||
|
Bispecific ADC |
PLB-005 |
Solid tumors |
|
|
|
|
|
PLB-006 |
Solid tumors |
|
|
|||
|
DAC |
PLB-007 |
TBD |
|
|
|
|
|
ADC(dual payloads) |
PLB-008 |
Solid tumors |
|
|
|
|
Add:
Building 4, Suhua Science Park , No.208 Tongyuan Road, Suzhou Industrial Park
Follow Us
©2022 PrimeLink BioTherapeutics Powered by：CEglobal